Literature DB >> 6312912

Pharmacological evidence for high affinity and low affinity a2-adrenoceptor binding sites in rat vas deferens.

D R Mottram.   

Abstract

Differential antagonistic activity against imidazoline- and phenethylamine-induced inhibition of field stimulated rat vas deferens is described. Competitive antagonism of the imidazolines, chlonidine and B-HT 920, was produced by the a2-selective antagonists yohimbine and phentolamine, whereas, only partial antagonism of a-methyl noradrenaline and adrenaline was observed. Higher concentrations of yohimbine (above 2 microM) and phentolamine (above 20 microM) failed to produce a further shift in the dose-response curves of these agonists. The rate of recovery of the twitch response following clonidine- or B-HT 920-induced inhibition was very slow, even after repeated washing of the tissue. On the other hand recovery following a-methyl noradrenaline or adrenaline was extremely rapid. The present results provide pharmacological evidence in support of the previously proposed existence of high and low affinity binding site on the a2-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6312912

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  3 in total

1.  Characterization of pigment aggregating alpha 2-adrenoceptors of fish melanophores by use of different agonists after partial irreversible receptor inactivation.

Authors:  J O Karlsson; R G Andersson; N Grundström
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

2.  Blocking action of berberine on alpha 2- and alpha 1-adrenoceptors in rat vas deferens and anococcygeus muscle.

Authors:  W X Yao; D C Fang; B Cheng; M X Jiang
Journal:  J Tongji Med Univ       Date:  1987

3.  Evidence for a receptor mediated action of norepinephrine distinct from alpha- and beta-adrenoceptors.

Authors:  R A Bond; K G Charlton; D E Clarke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.